Hoth Therapeutics: D. Boral Capital Raises Buy Rating to $5, PT Up to $5

Hoth Therapeutics: D. Boral Capital Raises Buy Rating to $5, PT Up to $5

Hoth Therapeutics Inc. (HOTH) has seen a significant boost in its stock price following a recent upgrade in its buy rating by D. Boral Capital. The firm has increased its price target (PT) for HOTH to $5, up from its previous rating of $4. This move comes on the heels of the company's recent quarterly earnings report and a series of positive market developments.

In its earnings report for the quarter ended June 30, HOTH reported an adjusted loss of 17 cents per share, which was higher than the same quarter last year but still missed analyst expectations by 31.7%. Despite the earnings miss, the company's stock has gained 55.1% so far this year, indicating strong investor confidence in the company's long-term prospects.

The upgrade by D. Boral Capital reflects the firm's bullish view on HOTH's growth potential. The analyst firm noted that the company's recent developments, including its ongoing research and development efforts, position it well for future growth. The upgrade also comes as HOTH's stock price has been trending upwards, with the company's shares up by 0.9% in the quarter and 55.1% year-to-date.

However, it is essential to note that HOTH's stock has been volatile in recent weeks, with a significant drop of 0.775% on Friday, August 15, 2025. The stock has also seen increased trading volume, with 187,000 shares bought and sold for approximately $239,830. This volatility may indicate a potential shift in the stock's trend, but it is too early to determine the direction of the trend.

In conclusion, the upgrade by D. Boral Capital provides a positive outlook for HOTH's stock, but investors should remain cautious due to the stock's recent volatility. The company's strong growth potential and positive analyst ratings make it an attractive investment opportunity, but the recent price drop and increased trading volume should be closely monitored.

References:

[1] https://stockinvest.us/stock/HOTH
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U42AK:0-hoth-therapeutics-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/